Next 10 |
2024-07-19 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it’s ...
2024-07-17 13:30:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals. This is mainly to explo...
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...
2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods. These are precisely the sort of corpo...
2024-07-14 09:15:00 ET Growth stocks aren't created equal, but great businesses can stand the test of time in a portfolio and reward shareholders many times over through the years. Healthcare stocks with strong business profiles, robust revenue growth, and healthy profits can offer greater ...
2024-07-13 14:03:47 ET More on Amgen, Biogen, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Merck: Positive Developments, But Watch The Q2 Earnings Biogen Stock: Cheapish, But With Few Growth Prospects This weight loss stock is the...
2024-07-13 10:00:00 ET Summary CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper ...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...
2024-07-09 12:31:46 ET Summary Vertex's stock has risen 18% since last December, matching the SPY index, bolstered by promising Phase 2 data for VX-548 in diabetic peripheral neuropathy. Vertex is expanding into gene therapies and other rare disease treatments, recently acquiring ...
2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...